Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) View the PDF document
Table of Contents
View the documentAbstract
View the documentAcknowledgments
View the documentInformation on authors
View the documentExchange rates used in the report
Open this folder and view contentsChapter 1: Policies for praziquantel*
Open this folder and view contentsChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Open this folder and view contentsChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Open this folder and view contentsChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Open this folder and view contentsChapter 5: The international supply of praziquantel*
Open this folder and view contentsChapter 6: Demand for praziquantel and national distribution*
Open this folder and view contentsChapter 7: Prices and production costs of praziquantel*
View the documentOther documents in the DAP Research Series
View the documentDAP Research Series No. 26
 

Other documents in the DAP Research Series

N°. 1

Injection practices research

N°. 2

How to investigate drug use in communities (also available in French)

N°. 3

Operational research on the rational use of drugs

N°. 4

Development of indicators for monitoring national drug policies

N°. 5

People's perception and use of drugs in Zimbabwe

N°. 6

Operational research in the Action Programme on Essential Drugs: Report of an informal consultation

N°. 7

How to investigate drug use in health facilities: Selected drug use indicators (also available in French and Spanish)

N°. 8

Stability of injectable oxytocics in tropical climates: Results of field surveys and simulation studies on ergometrine, methylergometrine and oxytocin

N°. 9

Prescription des antibiotiques dans trois pays d'Afrique de l'Ouest: Mauritanie, Niger et Sénégal

N°. 10

Self-medication and its impacts on essential drugs schemes in Nepal

N°. 11

Injection practices: A case study in Thailand

N°. 12

Stability of oral oxytocics in tropical climates

N°. 13

Stability of essential drugs in tropical climates: Zimbabwe

N°. 14

Injection practices: A case study of Uganda

N°. 15

Community health workers and drugs: A case study of Thailand

N°. 16

Use of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce

N°. 17

Impact of a short course in pharmacotherapy for undergraduate medical students: An international multicentre study

N°. 18

La qualité des médicaments sur le marché pharmaceutique africain. Etude analytique dans trois pays: Cameroun, Madagascar, Tchad

N°. 19

Operational research projects in the Action Programme on Essential Drugs: An annotated inventory

N°. 20

Injection practices in the developing world. A comparative review of field studies in Uganda and Indonesia

N°. 21

Le secteur pharmaceutique privé commercial au Maroc: Dynamique de développement et effets sur l’accessibilité des médicaments

N°. 22

La libéralisation du secteur pharmaceutique en Algérie: Effets sur la disponibilité et les prix des médicaments

N°. 23

Le secteur pharmaceutique privé commercial au Sénégal: Dynamique de développement et effets sur l’accès aux médicaments essentiels

N°. 24

Public education in rational drug use: A global survey

N°. 25

Comparative analysis of national drug policies - Second workshop, Geneva, 10-13 June 1996

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014